- Home
- DOGZ vs TSHA Comparison
DOGZ vs TSHA Comparison
Compare DOGZ & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOGZ
- TSHA
- Stock Information
- Founded
- DOGZ 2003
- TSHA 2019
- Country
- DOGZ China
- TSHA United States
- Employees
- DOGZ N/A
- TSHA N/A
- Industry
- DOGZ Miscellaneous manufacturing industries
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- DOGZ Consumer Discretionary
- TSHA Health Care
- Exchange
- DOGZ Nasdaq
- TSHA Nasdaq
- Market Cap
- DOGZ N/A
- TSHA 356.7M
- IPO Year
- DOGZ 2017
- TSHA 2020
- Fundamental
- Price
- DOGZ $25.09
- TSHA $1.13
- Analyst Decision
- DOGZ
- TSHA Strong Buy
- Analyst Count
- DOGZ 0
- TSHA 8
- Target Price
- DOGZ N/A
- TSHA $6.63
- AVG Volume (30 Days)
- DOGZ 77.6K
- TSHA 2.5M
- Earning Date
- DOGZ 05-16-2025
- TSHA 05-13-2025
- Dividend Yield
- DOGZ N/A
- TSHA N/A
- EPS Growth
- DOGZ N/A
- TSHA N/A
- EPS
- DOGZ N/A
- TSHA N/A
- Revenue
- DOGZ $20,258,926.00
- TSHA $8,333,000.00
- Revenue This Year
- DOGZ N/A
- TSHA N/A
- Revenue Next Year
- DOGZ N/A
- TSHA N/A
- P/E Ratio
- DOGZ N/A
- TSHA N/A
- Revenue Growth
- DOGZ 46.16
- TSHA N/A
- 52 Week Low
- DOGZ $5.40
- TSHA $1.05
- 52 Week High
- DOGZ $58.50
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- DOGZ 41.66
- TSHA 30.27
- Support Level
- DOGZ $26.00
- TSHA $1.10
- Resistance Level
- DOGZ $30.39
- TSHA $1.87
- Average True Range (ATR)
- DOGZ 2.64
- TSHA 0.18
- MACD
- DOGZ -0.10
- TSHA -0.06
- Stochastic Oscillator
- DOGZ 8.79
- TSHA 3.42
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.